Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
暂无分享,去创建一个
P. Pedrazzoli | F. Locatelli | A. Nocera | A. Tagliamacco | S. Basso | P. Comoli | R. Schiavo | S. Siena | R. Maccario | F. del Galdo | R. De Palma | O. Carminati | G. Abbate | R. Palma | F. Galdo | Salvatore Siena
[1] A. Davis,et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. , 2003, Blood.
[2] P. Tam,et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. , 2002, Cancer research.
[3] J. Thompson,et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[4] F. Baldanti,et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. , 2002, Blood.
[5] K. Yuen,et al. Adoptive transfer of autologous Epstein‐Barr virus–specific cytotoxic T cells for nasopharyngeal carcinoma , 2001, International journal of cancer.
[6] H. Heslop,et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein‐Barr virus–positive Hodgkin's lymphoma , 2001, International journal of cancer.
[7] S. Leung,et al. CTL Control of EBV in Nasopharyngeal Carcinoma (NPC): EBV-Specific CTL Responses in the Blood and Tumors of NPC Patients and the Antigen-Processing Function of the Tumor Cells1 , 2000, The Journal of Immunology.
[8] I. Flinn,et al. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. , 2000, Blood.
[9] S Kimbrough,et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. , 1998, Blood.
[10] S. Burrows,et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. , 1998, Cancer research.
[11] D. Srivastava,et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.
[12] D. Moss,et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.
[13] J. Gorski,et al. Restricted and conserved T-cell repertoires involved in allorecognition of class II major histocompatibility complex. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[14] S. Taylor. Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.
[15] Pelayo Vilar,et al. Nasopharyngeal Carcinoma , 1966 .
[16] Ch'en Ch'in-Ts'ai,et al. NASOPHARYNGEAL CARCINOMA , 1959 .